The Connecticut-based asset manager added a 165,000-share position in Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) to its portfolio during the first three months of 2016, which was valued at $4.34 million on March 31.
It could be a dilution too @ 19+ a share. No knows for sure!
So, they can justify to the public that everything had been done to try approve this drug including a conditional approval, but we were unable to do so. I'm out as of now, Good luck to all long.
Are a brave man/woman, and I hope that you are going to be rewarded handsomely tomorrow morning. Those who bailed out before the close today, you may lose plenty tomorrow, or may be you have made the right move and saved BIG time. We are gonna find out in 18 hours or so. I'm one of those who held my shares tightly. Good luck y'all.
I'm in all the way today. Upped my shares from 1k to 5k in increment every time it dips. My average now is $18.25,There is no way possible the FDA is going to reject us knowing that BMRN dropped the bomb today by parting away from its own drug.